Postgraduate research opportunities 

Cardiovascular & Medical Sciences PhD

blood cells

Our strength is in identifying and designing novel therapeutic strategies that will lead to clinical trials.

Research projects

Self-funded PhD opportunities

MicroRNAs and Cardiovascular Disease

Supervisor: Prof Eleanor Davies, Dr Scott MacKenzie

Research area:Hormones and the Cardiovascular System

Project outline: The steroid hormone aldosterone is produced by the adrenal gland and plays an important role in blood pressure control. Increased levels of the hormone are associated with hypertension, atrial fibrillation, ventricular hypertrophy, stroke, obesity and diabetes.

Therefore, understanding the mechanisms involved in the regulation of this important hormone is essential. Recent studies have shown that non-coding RNAs (microRNAs and long non-coding RNAs) can have a significant impact on mammalian regulatory mechanisms and our current studies show that this is also true of aldosterone production.

In this project, we wish to examine the role of non-coding miRNAs in aldosterone production and related cardiovascular disease, study their effect on cellular processes and investigate their utility as circulating biomarkers of disease. This project will combine our extensive experience of cardiovascular and hormone research with cutting edge molecular/cellular biology and bioinformatic methods.

Summary aim: This project has the potential to identify novel molecular mechanisms that regulate the production of the steroid hormone aldosterone. Understanding the regulation of aldosterone production is central to unravelling its role in common conditions such as hypertension, stroke, obesity and diabetes. A detailed knowledge of its regulation and production will aid the development of new therapeutic interventions for these common conditions.

Techniques used: Cell culture, qRT-PCR, transfection, ELISA, Western blotting, DNA sequencing, RNA-Seq screening, Bioinformatics

References: 

  1. Robertson S, Diver LA, Alvarez-Madrazo S, Livie C, Ejaz A, Fraser R, Connell JM, MacKenzie SM, Davies E. Regulation of Corticosteroidogenic Genes by MicroRNAs. Int J Endocrinol. 2017
  2. MacKenzie SM, van Kralingen JC, Davies E.Robertson S, MacKenzie SM, Alvarez-Madrazo S, Diver LA, Lin J, Stewart PM, Fraser R, Connell JM, Davies E. MicroRNA-24 is a novel regulator of aldosterone and cortisol production in the human adrenal cortex. Hypertension. 2013 Sep;62(3):572-8.
  3. Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev. 2008 Apr;29(2):133-54.

Contact address and email:

Professor Eleanor Davies
Professor of Molecular Endocrinology
Institute of Cardiovascular and Medical Sciences
BHF Glasgow Cardiovascular Research Centre
126 University Place
Glasgow G12 8TA
Eleanor.davies@glasgow.ac.uk

Plasma high density lipoprotein as a vascular protective agent in gestational diabetes and preeclampsia

Supervisor: Dilys Freeman

Research area: Metabolic Disease and Diabetes Research

Project outline: Pre-eclampsia, a multi-system disorder particular to human pregnancy, is characterised by widespread endothelial dysfunction, resulting in hypertension due to vasoconstriction, proteinuria attributable to glomerular damage and oedema secondary to increased vascular permeability. Gestational diabetes mellitus (GDM) which occurs in 5% of pregnancies is a major risk factor for preeclampsia and a history of GDM is a risk factor for preeclampsia in a future pregnancy.

In pre-eclampsia and GDM the maternal metabolic adaptation to pregnancy is abnormal with development of metabolic syndrome features including reduced high density lipoprotein (HDL) concentration. Vascular dysfunction in pre-eclampsia and GDM has been observed both at the physiological level and in isolated blood vessels.

In pre-eclampsia there appears to be a plasma-borne factor that either inhibits vascular function or fails to protect it. Pre-incubation of myometrial vessels from healthy pregnancy with plasma from women with pre-eclampsia, even if plasma was sampled at a gestation prior to the clinical manifestation of pre-eclampsia, inhibited endothelium-dependent relaxation. Interestingly, an association between the concentration of the major protein constituent of HDL, apoAI, in plasma and vaso-relaxation has been observed. We hypothesise that in healthy pregnancy maternal vessel function is protected by plasma HDL.  In pre-eclampsia and GDM this protection is lost (due to decreased HDL concentration or inferior HDL function) and leads to impaired maternal vascular function

Project aims

  • To compare the effects of healthy pregnant HDL with HDL from pregnancies complicated by GDM or preeclampsia on maternal peripheral (adipose tissue) vessel function.
  • To compare HDL functional properties in healthy, GDM and preeclampsia pregnancies.

Techniques used: Lipoprotein isolation, extracellular vesicle biology, proteomics, wire myography.

References: 

  1. Wan Sulaiman WN, Caslake MJ, Delles C, Karlsson H, Mulder MT, Graham D, Freeman DJ. Does high density lipoprotein protect vascular function in healthy pregnancy? Clinical Science 2016;130(7):491-7
  2. Rodie VA, Freeman DJ, Sattar N, Greer IA. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy? Atherosclerosis 2004 175:189-202
  3. Morgan HL, Butler E, Ritchie S, Herse F, Dechend R, Beattie E, McBride MW,Graham D. Modeling Superimposed Preeclampsia Using Ang II (Angiotensin II)Infusion in Pregnant Stroke-Prone Spontaneously Hypertensive Rats. Hypertension. 2018 Jul;72(1):208-218. 

Contact address and email:

Dilys.Freeman@glasgow.ac.uk
Institute of Cardiovascular and Medical Sciences
Wolfson Link Building, University of Glasgow.

Regulation of Aldosterone Production by novel RNA Molecules.

Supervisor: Prof Eleanor Davies, Dr Scott MacKenzie

Research area: Cardiovascular Endocrinology

Project outline: The steroid hormone aldosterone is produced by the adrenal gland and plays an important role in blood pressure control. Increased levels of the hormone are associated with hypertension, cardiovascular disease, stroke, obesity and diabetes and play a role in the pathogenesis of these common diseases. Therefore, understanding the molecular mechanisms involved in the regulation of this important hormone is essential.
Recent studies have shown that non-coding RNAs (microRNAs and long non-coding RNAs) can have a significant impact on mammalian regulatory mechanisms and our current studies show that this is also true of aldosterone production. This project will combine our extensive experience of aldosterone research with cutting edge molecular biology and bioinformatic methods to examine non-coding miRNA profiles in the adrenal gland and in the circulation of patients with excess aldosterone production. The effect of non-coding RNAs whose profile is altered, on aldosterone production and other cellular processes e.g cell divison, apoptosis, angiogenesis will be examined using standard laboratory techniques.

Summary aim: This project has the potential to identify novel molecular mechanisms that regulate the production of the steroid hormone aldosterone. Understanding the regulation of aldosterone production is central to unravelling its role in common conditions such as hypertension, stroke, obesity and diabetes. A detailed knowledge of its regulation and production will aid the development of new therapeutic interventions for these common conditions.

Techniques used: Cell culture, qRT-PCR, transfection, ELISA, Western blotting, DNA sequencing, RNA-Seq screening, Bioinformatics

References:

  • Robertson S, MacKenzie SM, Alvarez-Madrazo S, Diver LA, Lin J, Stewart PM,Fraser R, Connell JM, Davies E. MicroRNA-24 is a novel regulator of aldosterone and cortisol production in the human adrenal cortex. Hypertension. 2013 Sep;62(3):572-8.
  • Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev. 2008 Apr;29(2):133-54.
  • Alvarez-Madrazo S, Mackenzie SM, Davies E, Fraser R, Lee WK, Brown M, Caulfield MJ, Dominiczak AF, Farrall M, Lathrop M, Hedner T, Melander O, Munroe PB, Samani N, Stewart PM, Wahlstrand B, Webster J, Palmer CN, Padmanabhan S, Connell JM. Common polymorphisms in the CYP11B1 and CYP11B2 genes: evidence for a digenic influence on hypertension. Hypertension. 2013 Jan;61(1):232-9.

Contact address and email:

Professor Eleanor Davies
Professor of Molecular Endocrinology
Institute of Cardiovascular and Medical Sciences
BHF Glasgow Cardiovascular Research Centre
126 University Place
Glasgow G12 8TA
Eleanor.davies@glasgow.ac.uk

Adipose tissue function in preeclampsia

Supervisor: Dilys Freeman

Research area: Diabetes, Renal, Endocrinology and Metabolism

Project outline: Preeclampsia is a leading cause of pregnancy-related maternal and offspring mortality and morbidity, occurs in 2-10% of pregnancies and is unique to humans. It is a multi-factorial disease with a number of presenting phenotypes caused by a primary defect in trophoblast invasion followed by an atypical maternal vascular response resulting in hypertension and proteinuria. Maternal obesity is a risk factor for preeclampsia and an abnormal maternal metabolic adaptation to pregnancy, reflective of metabolic syndrome, is a key feature of the disease. Maternal gestational hyperlipidaemia is a physiological response and provides for the energy demands of the fetus as well as supplying lipid precursors necessary for fetal development. In healthy pregnancy, mothers store fatty acids in adipose tissue and, as a consequence of the action of pregnancy hormones, maternal insulin resistance develops in mid to late gestation. This leads to increased adipocyte lipolysis, up-regulation of VLDL synthesis by the liver and gestational hypertriglyceridaemia. We have previously shown that in preeclampsia, there is evidence that mothers are less able to expand their adipose tissue and their adipocytes are more insulin resistant resulting in increased lipolysis. Excessive lipolysis and reduced capacity to store fatty acids in adipose tissue, such as is seen in type 2 diabetes, can lead to ectopic fat accumulation in the liver and other tissues with downstream pathological consequences resulting from lipotoxicity. The consequences of inappropriate fatty acid handling in pregnancy can include vascular dysfunction, increased insulin resistance and defects of long chain polyunsaturated fatty acid metabolism.

Project aims: The aim of this project is to explore in more detail the adipose tissue defects in preeclampsia. In particular the regulation of adipocyte lipolysis and lipogenesis will be studied and the mechanisms for the limited expansion or pre-adipocytes to form mature adipocytes examined.

Techniques used: Metabolic assays in adipocytes using ex-vivo tissue biopsies. Gene and protein expression of regulators of adipocyte differentiation. Cell culture of preadipocytes.

References:

  • Jarvie E, Hauguel-de-Mouzon S, Nelson SM, Sattar N, Catalano PM, Freeman DJ Lipotoxicity in obese pregnancy and its potential role in adverse pregnancy outcome. Clinical Science 2010;119:123-9
  • Huda SS, Forrest R, Paterson N, Jordan F, Sattar N, Freeman DJ. In preeclampsia, maternal third trimester subcutaneous adipocyte lipolysis is more resistant to suppression by insulin than in healthy pregnancy Hypertension 2014;63(5):1094-101
  • Mackay VA, Huda SS, Stewart FM, Tham K, McKenna L, Martin I, Jordan F, Brown E.A, Hodson L, Greer IA, Meyer BJ, Freeman DJ. Preeclampsia is associated with compromised maternal synthesis of long chain polyunsaturated fatty acids leading to offspring deficiency Hypertension 2012;60(4):1078-85

Contact address and email:

Dilys.Freeman@glasgow.ac.uk
Institute of Cardiovascular and Medical Sciences
West Medical Building, University of Glasgow.

Runx1 and Heart Disease Post-Myocardial Infarction

Supervisor: Dr C Loughrey, Dr S Nicklin, Ewan Cameron

Research area: Heart Research

Project outline: Coronary heart disease (CHD) leading to myocardial ischaemia is the predominant cause of heart failure (HF) and premature mortality in the UK. CHD occurs when the blood vessels of the heart (coronary arteries) become narrowed by fatty material (atheroma) and reduce blood flow to heart muscle (myocardial ischaemia). If the coronary artery is occluded then an area of lethal tissue injury in heart muscle called a myocardial infarction (MI) can be produced. The subsequent structural and functional changes in the surviving heart muscle can lead to poor cardiac pump function and HF. Novel therapeutic strategies to preserve cardiac pump function are urgently needed to treat patients with myocardial infarction and thereby improve patient survival rates and quality of life.
The Runx family of genes (Runx1,2&3) encode for DNA binding transcription factors (Runx1,2&3) which regulate gene expression. Recently, increased Runx1 expression has been demonstrated in the hearts of patients with MI. In line with these data, our recent work demonstrates increased Runx1 expression in a mouse model of MI. However, despite these observations, the role Runx1 plays in heart function remains unknown. We have made a novel and exciting discovery that higher Runx1 expression levels correlate with poor cardiac pump function. In order to corroborate this finding, we have produced a heart-specific knockout of Runx1. When MI is induced in this transgenic model, cardiac pump function is markedly improved suggesting that reducing Runx1 expression in the heart is a potentially novel therapeutic approach to limit the progression of cardiac dysfunction in patients with MI.

Project aims: This studentship will investigate whether reduction of Runx1 levels in the heart via somatic gene transfer using viral gene transfer vectors can improve cardiac pump function in a mouse model of MI.

Techniques used: The project will enable the student to be trained in in vivo rodent models of MI, integrative physiology, molecular biology and gene transfer approaches.

References:

  • McMurray et al. European journal of heart failure. 2012;14:803-869.
  • Kubin et al. Cell stem cell. 2011;9:420-432.
  • Loughrey et al. The Journal of physiology. 2004;556:919-934.

 

Contact address and email:

christohper.loughrey@glasgow.ac.uk

Role of IL-33 in cardiovascular inflammation

Supervisor: Dr Ashley Miller

Research area: Cardiovascular inflammation

Project outline: The main focus of my research is to investigate the role of the immune system in cardiovascular diseases. Evidence is now accumulating that during obesity tissues such as arteries and adipose develop chronic low-grade inflammation that likely contributes to metabolic consequences such as type 2 diabetes. Immune cells, such as macrophages and T cells, and the resident vascular cells and adipocytes secrete a variety of pro-inflammatory cytokines and chemokines. Recent studies demonstrate that the infiltrating T cells display a Th1 pattern of activation with enhanced IFN? production, and that an imbalance may exist in obese adipose between dominant Th1 responses and reduced Treg or Th2 responses. This in turn leads to macrophage recruitment and a switch from a protective alternatively activated (M2) macrophage to a classically activated (M1) pro-inflammatory phenotype. We have shown that the IL-1 family cytokine, IL-33, and its receptor ST2 can play a key protective role in systemic and vascular inflammation in atherosclerosis and obesity, and current work is focused on identifying the mechanisms of IL-33-induced protection. In particular we plan to study the phenotype of cellular immune infiltrates induced into adipose tissue and arteries, and elucidate the metabolic consequences of IL-33 signalling.

Project aims:

  • To study the metabolic consequences of IL-33 signalling in adipose tissue and arteries
  • To identify the immune cells recruited to adipose tissue and arteries in response to IL-33
  • To elucidate the chemokines responsible for recruitment of immune cells to adipose tissue in response to IL-33.

Techniques used:

  • FACS
  • PCR
  • Immunohistochemistry
  • Luminex
  • Cell culture – macrophages, adipocytes, endothelial cells
  • Animal models of obesity/diabetes and atherosclerosis

References:

  • Miller AM, Asquith DL, Hueber AJ, Holmes W, McKenzie A, Xu D, Sattar N, McInnes IB, Liew FY (2010) IL-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ. Res. 107: 650-658.
  • Weir RAP, Miller AM, Murphy GEJ, Clements S, Steedman T, Connell JMC, McInnes IB, Dargie HJ, McMurray JJC (2010) Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling following acute myocardial infarction. JACC. 55: 243-250.
  • Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, Baker AH, McInnes IB and Liew FY (2008) IL-33 Reduces the Development of Atherosclerosis. J. Exp. Med. 205: 339-346.

Contact address and email:

Institute of Cardiovascular & Medical Sciences
C437, BHF Glasgow Cardiovascular Research Centre
126 University Place
University of Glasgow,
Glasgow, G12 8TA
Ashley.Miller@glasgow.ac.uk

Assessing the counter-regulatory renin angiotensin system in cardiovascular disease

Supervisors: Dr Stuart Nicklin (with Dr Christopher Loughrey, Professor Graeme Milligan, Prof Andrew Baker)

Research area: Institute of Cardiovascular & Medical Sciences

Project outline: The renin angiotensin system (RAS) is a hormonal cascade mediating cardiovascular function. The RAS is key to the development of cardiovascular diseases, including hypertension, cardiac remodelling and atherosclerosis. A counter-regulatory RAS exists, centered on the angiotensin converting enzyme (ACE) homologue ACE2 and angiotensin 1-7 [Ang-(1-7)], highlighting additional key mediators of the RAS which may be therapeutic targets in cardiovascular disease. We have also discovered that Ang-(1-9), a metabolite of the Angiotensin II precursor angiotensin I, is a RAS hormone. We have demonstrated that Ang-(1-9) is able to antagonise the pathophysiological effects of AngII in cardiomyocytes, fibroblasts and vascular smooth muscle cells via the angiotensin type 2 receptor. We are now investigating the effects of Ang-(1-9) in cardiovascular disease models including hypertensive cardiomyopathy, myocardial infarction and acute vascular injury in order to understand its molecular mode of action and its therapeutic potential.

Project aims: To dissect mechanisms of action of angiotensin-(1-9) in cardiovascular disease and explore therapeutic options.

Techniques used: Cell culture in both primary cells and cell lines and in vivo models of cardiovascular disease, molecular biology techniques, construction and testing of replication deficient viral gene transfer vectors.

References:

  • C McKinney, C Fattah, C Loughrey, SA Nicklin. (2014). Cardiac and vascular remodelling: effects of the counter-regulatory renin angiotensin system peptides, Ang-(1-7) and Ang-(1-9). CLINICAL SCIENCE, 126: 815-827.
  • Flores-Munoz, M., Smith, N. J., Haggerty, C., Milligan, G, and Nicklin, S. A. (2011) Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. The Journal of Physiology, 589 (4). pp. 939-951. ISSN 0022-3751
  • M Flores-Muñoz, LM Work, K Douglas, L Denby, AF Dominiczak, D Graham, SA Nicklin. (2012). Angiotensin-(1-9) attenuates cardiac fibrosis in the SHRSP via the angiotensin type 2 receptor. HYPERTENSION, 59(2):300-307.

 

Contact address and email:

Stuart A Nicklin BSc (Hons) PhD
Reader
Institute of Cardiovascular and Medical Sciences
BHF Glasgow Cardiovascular Research Centre
College of Medical, Veterinary and Life Sciences
University of Glasgow
126 University Place
Glasgow G12 8TA
Email: stuart.nicklin@glasgow.ac.uk
Tel: +44 (0)141-330-2521
Fax: +44 (0)-141-330-6997

Developing Therapeutic approaches for haemorrhagic stroke

Supervisor: Dr. Tom Van Agtmael

Research area: Mouse genetics, haemorrhagic stroke, molecular cell biology, extracellular matrix, vascular disease, collagen, endoplasmic reticulum stress

Project outline: Stroke costs UK Society ~£8 billion annually with haemorrhagic stroke accounting for 15% of adult and 50% of paediatric stroke. There are no treatment available for haemorrhagic stroke, in part due to a poor understanding of the underlying molecular cause.
Collagen IV is the major component of a type of extracellular matrix called the basement membrane that provides essential structural support to blood vessels. We and others have shown that mutations in COL4A1 or COL4A2 (encoding collagen IV proteins) cause familial and sporadic haemorrhagic, indicating these mutations may be more common than previously expected and a potential contribution to stroke in the general population (1). Our results also reveal that endoplasmic reticulum (ER)-stress due to intracellular accumulation of mutant collagen IV is associated with disease development, and that treatment of collagen IV mutant cells can reduce ER-stress (2). This provides a golden opportunity to identify the disease causing mechanisms and explore therapeutic approaches for collagen IV diseases including haemorrhagic stroke.
We have brought together a unique cohort of cell lines from patients and animal models with Col4a1 mutations to investigate the disease mechanisms of these mutations and determine how cells respond to these mutations. The identified pathways will then be modified in cell line and animal models to investigate their role in disease development and identify their potential as a therapeutic target. As FDA approved compounds are available, this will directly inform on and may identify therapeutic approaches for haemorrhagic stroke.

Project aims:

  • Exploring genetic and high throughput approaches to identify pathways that influence disease development
  • Identify the ability of small compounds to prevent the pathological effects of collagen IV mutation in cells.
  • Modification of disease development in animal models

Techniques used: State of the art imaging techniques including 3-dimensional electron microscopy, confocal microscopy and atomic force microscopy. Molecular cell biology, animal models, MRI imaging, transcriptomics.

References:

  • Plaisier E, et al. Role of COL4A1 Mutations in the Hereditary Angiopathy with Nephropathy, Aneurysm and Cramps (HANAC) Syndrome. New Eng J Med 2007, 357, 2687-2695
  • Murray LS et al. Chemical chaperone treatment reduces intracellular accumulation of mutant collagen IV and ameliorates the cellular phenotype of a COL4A2 mutation that causes haemorrhagic stroke. Hum Mol Genet 2014, 23:283-92

Contact address and email:

tom.vanagtmael@glasgow.ac.uk
Dr. Tom Van Agtmael
Institute of Cardiovascular & Medical Sciences
College of Medical, Veterinary and Life Sciences
Davidson Building
University of Glasgow
University Avenue
Glasgow, G12 8QQ
United Kingdom
Phone: +44 (0)141 330 6200

Overview

Cardiovascular disease is projected to remain the single leading cause of death over the next two decades, accountable for considerable disability and reduction in the quality of life, therefore research is vital to advance its diagnosis, treatment and prevention.  

The Institute of Cardiovascular & Medical Sciences (ICAMS) is a successful and vibrant research institute with outstanding training and learning opportunities. Our purpose-built British Heart Foundation (BHF) Cardiovascular Research Centre houses state-of-the-art laboratories and facilities and we are one of only six BHF Centres of Excellence in the UK. Our research strengths have been integrated into substantial, well-resourced thematic programmes that build on the strengths of individual, clinical and non-clinical principal investigators. Working in basic, translational and clinical research, our strength is in elucidating mechanisms of cardiovascular disease, identifying biomarkers of disease, identifying therapeutic targets and developing and designing novel therapeutic strategies that will lead to clinical trials.

Study options

PhD

  • Duration: 3/4 years full-time; 5 years part-time

Individual research projects are tailored around the expertise of principal investigators within the institute. Basic and clinical projects are available for study. A variety of approaches are used, including molecular biology, biochemistry, epidemiology, mathematical modelling, bioinformatics, genetics, cell biology (including advanced in vitro and in vivo imaging), immunology and polyomics (genomics, transcriptomics, proteomics, metabolomics etc).

Specific areas of interest include:

  • vascular science and medicine
  • cardiovascular biology and cell signalling
  • cardiovascular gene therapy for the treatment of vascular disease
  • basic and clinical cerebrovascular disease e.g. stroke 
  • stem cell therapies for cerebrovascular disease
  • genetics, genomics and systems medicine 
  • adrenal corticosteroids in cardiovascular disease
  • diabetes, obesity, metabolic and renal disease
  • cardiovascular imaging
  • cardiovascular clinical trials
  • sport & exercise science & medicine

MD (Doctor of Medicine)

Duration: 2 years full-time or 4 years part-time (for medically-qualified graduates only)

MSc (Research)

Duration: 1 year full-time / 2 years part-time

We run MSc (Research) programmes in Cardiovascular Medicine, Cardiovascular Sciences, Cardiovascular Pharmacology and Sports Science

Integrated PhD programmes (4 years)

  • Year 1: completion of taught masters level modules 
  • Years 2 to 4: research degree

Completion of taught masters level modules before entering a research PhD will provide you with a valuable introduction to academic topics and research methods, whilst providing key training in laboratory skills and the critical evaluation of research data.

Our ethos of research-led teaching will allow you to hone your research ideas and discuss these with potential PhD supervisors during year 1. Upon successful completion of the taught component, alongside students on our masters programmes, you will progress to your research degree in year 2 and complete an examinable piece of independent research by the end of the programme. 

Entry requirements

PhD programmes

Awarded or expected First-class or high Upper Second-class BSc degree.

Integrated PhD programmes

Upper Second-class Honours degree or international equivalent in a relevant subject area.

English Language requirements for applicants whose first language is not English.

Fees and funding

Fees

2019/20

  • £4,327 UK/EU
  • £21,020 outside EU

Prices are based on the annual fee for full-time study. Fees for part-time study are half the full-time fee.

Additional fees for all students:

  • Re-submission by a research student £500
  • Submission for a higher degree by published work £1,250
  • Submission of thesis after deadline lapsed £320
  • Submission by staff in receipt of staff scholarship £730
  • Research students registered as non-supervised Thesis Pending students (50% refund will be granted if the student completes thesis within the first six months of the period) £300

Depending on the nature of the research project, some students will be expected to pay a bench fee (also known as research support costs) to cover additional costs. The exact amount will be provided in the offer letter.

Alumni discount

A 10% discount is available to University of Glasgow alumni. This includes graduates and those who have completed a Junior Year Abroad, Exchange programme or International Summer School at the University of Glasgow. The discount is applied at registration for students who are not in receipt of another discount or scholarship funded by the University. No additional application is required.

Funding for EU students

The UK government has confirmed that EU nationals will remain eligible to apply for Research Council PhD studentships at UK institutions for 2019/20 to help cover costs for the duration of their study.

2018/19 fees

  • £4,260 UK/EU
  • £20,150 outside EU

Prices are based on the annual fee for full-time study. Fees for part-time study are half the full-time fee.

Additional fees for all students:

  • Submission by a research student £480
  • Submission for a higher degree by published work £1,200
  • Submission of thesis after deadline lapsed £300
  • Submission by staff in receipt of staff scholarship £680
  • Research students registered as non-supervised Thesis Pending students (50% refund will be granted if the student completes thesis within the first six months of the period) £270

Depending on the nature of the research project, some students will be expected to pay a bench fee to cover additional costs. The exact amount will be provided in the offer letter.

Funding

Support

Resources

Our laboratories are well resourced and we offer a wide range of cutting-edge research facilities, including core facilities in:

  • optical imaging
  • electrophysiology
  • magnetic resonance imaging
  • spectroscopy
  • cell biology
  • high throughput genotyping
  • phenotyping
  • clinical trials
  • a wide range of cellular, molecular and biochemical analysis tools

Our excellent facilities underpin a bench to bedside approach that will equip you with research specific and generic training and skills complementary to a wide range of career options. We can tailor your study pathway to the precise aspects of cardiovascular research that suit your objectives.

You will emerge equipped with the skills necessary for a career in the highly competitive field of cardiovascular science and medicine. Future career opportunities include basic and clinical cardiovascular research in academia or industry, education, NHS, clinical biochemistry, public health bodies, media and publishing, funding agencies and scientific charities.

Graduate School

The College of Medical, Veterinary & Life Sciences Graduate School provides a vibrant, supportive and stimulating environment for all our postgraduate students. We aim to provide excellent support for our postgraduates through dedicated postgraduate convenors, highly trained supervisors and pastoral support for each student.
 
Our overarching aim is to provide a research training environment that includes:

  • provision of excellent facilities and cutting edge techniques
  • training in essential research and generic skills
  • excellence in supervision and mentoring
  • interactive discussion groups and seminars
  • an atmosphere that fosters critical cultural policy and research analysis
  • synergy between research groups and areas
  • extensive multidisciplinary and collaborative research
  • extensive external collaborations both within and beyond the UK 
  • a robust generic skills programme including opportunities in social and commercial training

How to apply

Identify potential supervisors

All Postgraduate Research Students are allocated a supervisor who will act as the main source of academic support and research mentoring. You may want to identify a potential supervisor and contact them to discuss your research proposal before you apply. Please note, even if you have spoken to an academic staff member about your proposal you still need to submit an online application form.

You can find relevant academic staff members with our staff research interests search.


Gather your documents

Before applying please make sure you gather the following supporting documentation:

  1. Final or current degree transcripts including grades (and an official translation, if needed) – scanned copy in colour of the original document
  2. Degree certificates (and an official translation, if needed): scanned copy in colour of the original document
  3. Two references on headed paper (academic and/or professional).
  4. Research proposal, CV, samples of written work as per requirements for each subject area.

Submitting References

To complete your application we will need two references (one must be academic the other can be academic or professional).

There are two options for you to submit references as part of your application.  You can upload a document as part of your application or you can enter in your referee’s contact details and we will contact them to request a reference.

Option 1 – Uploading as part of the application form

Your references should be on official headed paper. These should also be signed by the referee. You can then upload these via theOnline Application form with the rest your documents to complete the application process.

Please be aware that documents must not exceed 5MB in size and therefore you may have to upload your documents separately. The online system allow you to upload supporting documents only in PDF format. For a free PDF writer go to www.pdfforge.org.

Option 2 - Entering contact details as part of the application form

If you enter your referees contact details including email on the application form we will email them requesting they submit a reference once you have submitted the application form.  When the referee responds and sends a reference you will be sent an email to confirm the university has received this.

After submitting your application form

Use our Applicant Self Service uploading documents function to submit a new reference. We can also accept confidential references direct to rio-researchadmissions@glasgow.ac.uk, from the referee’s university or business email account.  


Apply now

I've applied. What next?

If you have any other trouble accessing Applicant Self-Service, please see Application Troubleshooting/FAQs.

If you are requested to upload further documents

Log into the Applicant Self Service and scroll down to the Admissions Section. The screenshot below indicates the section on the page, and the specific area you should go to, highlighted in red:

Applicant self service

Documents must be uploaded in .jpg, .jpeg or .pdf format and must not exceed 5MB in size.  There is a maximum 10MB upload size for all documents with the application.

Decisions

Once a decision has been made regarding your application the Research Admissions Office will contact you by email.

If you are made an unconditional offer

You can accept your offer through the Applicant-Self-Service by clicking on the ‘Accept/Decline link’ for your chosen programme under the ‘Admissions Section’ at the bottom of the Applicant Self Service screen.  You can access the Applicant Self Service by using the link, username and password you used to apply and selecting the “Self Service” button below your application.

Please make sure you accept your unconditional offer within 4 weeks of receiving your offer. If you are an international student your CAS will not be issued until you have accepted an unconditional offer.

If you are made a conditional offer

If you accept a conditional offer then the offer status on Applicant-Self-Service will change to ‘incomplete’ to indicate that the application is incomplete until such time as all the conditions are met.

Your offer letter will list all the conditions that apply to your offer and you can upload the required document(s) through Applicant Self Service. If you have met the conditions satisfactorily, you will automatically be sent an unconditional offer.

If your application is unsuccessful

If your application is unsuccessful then we will send you an email to inform you of this which will outline the reason why we have been unable to offer you a place on this particular programme. Please note that your application status will be updated to 'Cancelled' on Applicant Self Service if the offer is rejected.

Deferring your offer

If you want to defer your start date, please contact us directly at rio-researchadmissions@glasgow.ac.uk. We need authorisation from your supervisor before we confirm your request to defer. Once we have this we will contact you by email to confirm.

How to register

After you have accepted an unconditional offer you will receive an email nearer to the start of your studies to tell you how to register online using the University's MyCampus website, the University’s student information system. That email will provide you with your personal login details and the website address. Please ensure that your email address is kept up to date as all correspondence is sent via email. You can update your email address through the Applicant Self Service Portal under the Personal Information section.


Contact us

International Students